AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 0.29 |
Market Cap | 8.13M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.03 |
PE Ratio (ttm) | -9.66 |
Forward PE | n/a |
Analyst | Hold |
Ask | 0.31 |
Volume | 802,164 |
Avg. Volume (20D) | 942,827 |
Open | 0.33 |
Previous Close | 0.32 |
Day's Range | 0.28 - 0.33 |
52-Week Range | 0.28 - 6.95 |
Beta | undefined |
About TTOO
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagn...
Analyst Forecast
According to 1 analyst ratings, the average rating for TTOO stock is "Hold." The 12-month stock price forecast is $5, which is an increase of 1624.73% from the latest price.
Next Earnings Release
Analysts project revenue of $3.70M, reflecting a 120.37% YoY growth and earnings per share of -0.49, making a -76.44% decrease YoY.